Profile data is unavailable for this security.
About the company
Silo Pharma, Inc. is a developmental stage biopharmaceutical company. The Company is focused on developing novel therapeutics that address underserved conditions including stress-induced psychiatric disorders, chronic pain conditions, and central nervous system (CNS) diseases. It is engaged in acquiring and/or developing intellectual property or technology rights from universities and researchers to treat rare diseases, including the use of psychedelic drugs, such as psilocybin, and the potential benefits they may have in certain cases involving depression, mental health issues and neurological disorders. The Company’s lead program, SPC-15, is an intranasal treatment targeting PTSD and stress-induced anxiety disorders. Its SP-26 is a time-release ketamine-loaded implant for fibromyalgia and chronic pain relief. Its two preclinical programs are SPC-14, an intranasal compound for the treatment of Alzheimer’s disease, and SPU-16, a CNS-homing peptide targeting multiple sclerosis (MS).
- Revenue in USD (TTM)72.12k
- Net income in USD-3.53m
- Incorporated2012
- Employees3.00
- LocationSilo Pharma Inc677 N. Washington BlvdSARASOTA 34236United StatesUSA
- Phone+1 (718) 400-9031
- Websitehttps://silopharma.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Titan Pharmaceuticals Inc | 87.00k | -4.95m | 5.95m | 4.00 | -- | 0.978 | -- | 68.41 | -6.41 | -6.41 | 0.1119 | 6.66 | 0.0197 | -- | 1.23 | 21,750.00 | -112.41 | -96.80 | -170.59 | -156.65 | -- | -- | -5,694.25 | -406.26 | -- | -415.19 | 0.00 | -- | -66.97 | -51.16 | 45.43 | -- | -65.61 | -- |
| CeCors Inc | -100.00bn | -100.00bn | 6.04m | 6.00 | -- | -- | -- | -- | -- | -- | -- | -0.0163 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 22.70 | -- | -- | -- |
| Genprex Inc | 0.00 | -27.63m | 6.04m | 26.00 | -- | 0.6323 | -- | -- | -19.18 | -19.18 | 0.00 | 4.55 | 0.00 | -- | -- | 0.00 | -153.97 | -92.06 | -202.83 | -98.32 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -29.99 | -- | -7.13 | -- |
| Enveric Biosciences Inc | 0.00 | -15.11m | 6.05m | 7.00 | -- | 0.8777 | -- | -- | -6.46 | -6.46 | 0.00 | 0.8887 | 0.00 | -- | -- | 0.00 | -122.02 | -104.94 | -178.49 | -156.88 | -- | -- | -- | -243.54 | -- | -- | 0.00 | -- | -- | -- | 7.14 | -- | -- | -- |
| Xenetic Biosciences Inc | 2.44m | -4.47m | 6.16m | 4.00 | -- | 0.7103 | -- | 2.52 | -2.92 | -2.92 | 1.59 | 5.63 | 0.2116 | -- | -- | 611,240.00 | -38.71 | -48.91 | -41.54 | -52.82 | -- | -- | -182.95 | -682.42 | -- | -- | 0.00 | -- | 48.80 | -- | 36.90 | -- | -- | -- |
| Virios Therapeutics Inc | 0.00 | -5.07m | 6.30m | 4.00 | -- | -- | -- | -- | -0.2673 | -0.2673 | 0.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 56.76 | -- | -- | -- |
| Silo Pharma Inc | 72.12k | -3.53m | 6.31m | 3.00 | -- | 1.20 | -- | 87.46 | -1.18 | -1.20 | 0.024 | 1.87 | 0.008 | -- | -- | 24,040.00 | -39.26 | -24.90 | -43.11 | -26.39 | 91.90 | 82.79 | -4,889.57 | -2,757.85 | -- | -- | 0.00 | -- | 0.00 | -- | 7.07 | -- | -- | -- |
| TFF Pharmaceuticals Inc | 885.71k | -19.93m | 6.32m | 19.00 | -- | 0.9689 | -- | 7.14 | -10.20 | -10.20 | 0.4371 | 2.11 | 0.0647 | -- | 3.72 | 46,616.32 | -145.46 | -79.57 | -181.57 | -83.41 | -- | -- | -2,249.83 | -8,687.66 | -- | -- | 0.00 | -- | 48.01 | -- | 33.13 | -- | -- | -- |
| Reliv International Inc | 35.13m | -175.48k | 6.35m | 208.00 | -- | 0.9165 | 15.88 | 0.1808 | -0.1005 | -0.1005 | 20.12 | 6.55 | 2.09 | 8.02 | 228.49 | -- | -1.05 | -4.65 | -1.47 | -6.06 | 40.90 | 41.98 | -0.4996 | -2.33 | 1.07 | -- | 0.1064 | -- | -2.94 | -9.37 | 76.65 | -- | -35.85 | -- |
| Galera Therapeutics Inc | 0.00 | -45.75m | 6.52m | 7.00 | -- | -- | -- | -- | -0.9971 | -0.9971 | 0.00 | -2.48 | 0.00 | -- | -- | 0.00 | -115.30 | -83.69 | -142.79 | -97.54 | -- | -- | -- | -- | -- | -6.49 | 9.23 | -- | -- | -- | 5.05 | -- | -29.84 | -- |
| Kazia Therapeutics Ltd (ADR) | 14.99k | -13.60m | 6.60m | 12.00 | -- | 0.7126 | -- | 440.04 | -0.8247 | -0.8247 | 0.0008 | 0.3511 | 0.0007 | -- | 73.97 | -- | -63.98 | -46.35 | -82.39 | -54.75 | -- | -- | -90,714.45 | -497.17 | -- | -- | 0.1297 | -- | 979.43 | -28.31 | 18.19 | -- | -- | -- |
| Longeveron Inc | 978.00k | -21.62m | 6.60m | 23.00 | -- | 0.8612 | -- | 6.75 | -9.58 | -9.58 | 0.4297 | 1.21 | 0.0621 | -- | 7.14 | 42,521.74 | -132.19 | -63.15 | -184.16 | -75.68 | 48.47 | 33.70 | -2,129.24 | -441.02 | -- | -- | 0.00 | -- | -41.98 | -19.78 | -17.92 | -- | 26.80 | -- |
| Hepion Pharmaceuticals Inc | 0.00 | -38.52m | 6.68m | 22.00 | -- | 1.15 | -- | -- | -9.49 | -9.49 | 0.00 | 1.37 | 0.00 | -- | -- | 0.00 | -117.64 | -61.43 | -145.05 | -68.82 | -- | -- | -- | -- | -- | -3,240.31 | 0.00 | -- | -- | -- | -7.92 | -- | -- | -- |
| Holder | Shares | % Held |
|---|---|---|
| Financial Advocates Investment Management LLCas of 31 Mar 2024 | 62.81k | 2.21% |
| The Vanguard Group, Inc.as of 31 Mar 2024 | 16.33k | 0.57% |
| Geode Capital Management LLCas of 31 Mar 2024 | 16.18k | 0.57% |
| SSgA Funds Management, Inc.as of 31 Mar 2024 | 12.50k | 0.44% |
| Tower Research Capital LLCas of 31 Mar 2024 | 4.43k | 0.16% |
| UBS Securities LLCas of 31 Mar 2024 | 374.00 | 0.01% |
| Westside Investment Management LLCas of 31 Mar 2024 | 94.00 | 0.00% |
| FWL Investment Management LLCas of 31 Mar 2024 | 80.00 | 0.00% |
| Wells Fargo Bank, NA (Private Banking)as of 31 Mar 2024 | 17.00 | 0.00% |
| JPMorgan Securities LLC (Investment Management)as of 31 Mar 2024 | 1.00 | 0.00% |
